Darunavir Suppliers & Bulk Manufacturers
Available Forms: Tablets / Oral suspension
Available Strengths: 75 mg, 150 mg, 600 mg, 800 mg, 100 mg/mL
Reference Brands: Prezista (USA/EU)
Category:
Anti Viral
Darunavir is available in Tablets / Oral suspension
and strengths such as 75 mg, 150 mg, 600 mg, 800 mg, 100 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Darunavir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Darunavir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Darunavir, marketed under the brand name Prezista, is an antiretroviral medication used in the treatment and prevention of HIV-1 infection. It is recommended for use in combination with other antiretroviral agents and is often co-administered with low doses of ritonavir or cobicistat to enhance its effectiveness by increasing plasma drug levels.
Darunavir is indicated for adults and children aged three years and older and is effective in both treatment-naive and treatment-experienced patients. It works as a protease inhibitor, blocking the HIV-1 protease enzyme that is essential for viral replication, thereby reducing viral load and helping maintain immune function.
In addition to treatment, darunavir may also be used for post-exposure prophylaxis, such as after needlestick injuries or other potential exposures to HIV. It is administered orally, typically once or twice daily, depending on the regimen. Its use as part of combination antiretroviral therapy has been shown to significantly improve clinical outcomes, making it a cornerstone in modern HIV management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing